Part 1: The Genetics Settled It — ME/CFS Is Neurological
You are sitting in a neurologist’s office. You have brought a binder — three years of symptom logs, two tilt-table reports, an autonomic breathing test, a sleep study showing alpha-delta intrusion. The neurologist glances at the papers, sets them down, and says: “Your tests are normal. Have you considered seeing a psychiatrist?”
This scene has played out tens of thousands of times. It is not malice — it is uncertainty dressed as certainty. Without a genetic anchor, doctors could always retreat to the null hypothesis: if we can’t find it in the blood, it must be in the mind. The largest genetic study of ME/CFS ever conducted just pulled that anchor out of the water.
1 What the GWAS found
The DecodeME consortium analysed over 15,000 participants — about 5,000 ME/CFS cases — against population controls, in the largest genome-wide association study of the disease to date (DecodeME Consortium, Ponting, et al. 2025). The headline finding is not a single “ME/CFS gene” — there isn’t one. The finding is about where the genetic variants that increase risk are expressed.
The risk variants cluster overwhelmingly in brain tissue, specifically in neurons. Not microglia, not astrocytes, not immune cells. Neurons.
The GWAS itself resolved the signal only to tissue: brain-enriched genes, not a specific cell type. A later post-GWAS cell-type enrichment analysis — a preprint, not the GWAS — pointed further, to medium spiny neurons (MSNs) of the striatum, the neurons involved in motor control, reward processing, and effort/reward decision-making (Maccallini 2026). When your brain computes whether an action is worth the energy cost, MSNs are doing that calculation.
2 What the finding means
This ends the “autoimmune vs neurological” framing that has paralysed the field for two decades.
Immune involvement is real but secondary. ME/CFS patients have elevated cytokines, autoantibodies, dysfunctional NK cells — the immune pathology is measurable and clinically important (Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome 2015). But this is acquired immune dysregulation, not genetically driven immune dysregulation. The genetic architecture points to the brain. The immune system is responding to something upstream — likely neuroinflammation, damage signals, or autonomic disruption originating in the CNS.
The primary locus of the disease is the brain. This changes where research resources should go. Before the GWAS, a researcher could reasonably argue that cytokine panels and autoantibody assays were the most promising route. That argument now has a genetic counterargument: the floor plan of the disease is written in neurons. Blood biomarkers may still be useful — they capture downstream pathology — but they are not capturing the root.
It does not rule out immune treatment. The distinction matters. Just because immune pathology is secondary does not mean targeting it is useless. Immunoadsorption, rituximab, low-dose naltrexone — these may still work, and they may work precisely because interrupting the immune downstream can break the feedback loops that maintain the disease. The genetics says: the immune system is a maintaining mechanism, not the primary lesion. Treat it by all means, but do not confuse treating a maintaining mechanism for treating the root cause.
3 The striatum and the basal ganglia hypothesis
The MSN signal — from the post-GWAS cell-type analysis, not the GWAS itself — is the most specific finding in this line of work, and it connects directly to a twenty-five-year-old hypothesis.
Chaudhuri and Behan proposed in 2000 that ME/CFS involves basal ganglia dysfunction, specifically a disruption of dopaminergic signalling in the striatum that impairs the brain’s ability to translate effort into action (Chaudhuri and Behan 2000). At the time, the hypothesis rested on functional imaging showing reduced striatal dopamine transporter binding and clinical observation of motor slowing, reduced motivation, and effort intolerance that did not fit a peripheral muscle pathology.
This post-GWAS cell-type analysis provides genetic support for a hypothesis that until now rested on functional imaging and clinical observation. The MSN is the cell type the hypothesis predicted — though the cell-type step is a preprint and needs independent replication.
But here is the caveat — and it is a substantial one.
Brain-neuron enrichment is not specific to ME/CFS — many brain disorders show it. The specific cell types differ, though: applying the same atlas pipeline, schizophrenia enriches cortical layer 2/3 excitatory neurons, depression layer 5/6, and alcohol use disorder medium spiny neurons (Duncan et al. 2025). So the striatum is not a generic node shared by all of them; ME/CFS and AUD converge on MSNs while schizophrenia and depression converge elsewhere in the cortex. The GWAS tells us where to look — the striatum — but not yet what is broken inside it. The cell type is localised. The mechanism within that cell type is not.
4 What changes for patients
The practical impact of a genetic finding in neurons is not a blood test or a drug. It is something more immediate: ammunition.
The “it’s psychological” argument loses its foundation. A genetic finding expressed in neurons is not a psychiatric finding. If the genetic architecture of ME/CFS says neurons — medium spiny neurons, striatal circuits, dopamine signalling — then the disease has more in common with Parkinson’s than with depression. No one tells a Parkinson’s patient to “think positive” or “try graded exercise.” The genetics makes the same dismissal harder for ME/CFS.
The “it’s deconditioning” argument also loses ground. Deconditioning does not produce a cell-type-specific genetic signal in the striatum. Deconditioning produces detrained muscle — measurable, real, but secondary to the neurological lesion that makes exercise impossible in the first place.
And the “it’s health anxiety” argument — the one that has followed ME/CFS since the Royal Free Hospital outbreak in 1955 (McEvedy and Beard 1970) — becomes transparently untenable. Health anxiety does not have a GWAS signal. The striatum does.
5 What changes for research
The resource allocation implications are straightforward:
Neuroimaging — functional and structural imaging of the striatum, basal ganglia circuitry, and dopamine pathways — becomes the highest-priority non-genetic research avenue. If the genetics says neurons, we need to see what those neurons are doing, in real time, in patients.
CSF metabolomics — particularly neurotransmitter metabolites, dopamine turnover products, and striatal signalling intermediates — becomes more informative than blood cytokine panels. The downstream is in the blood; the upstream is in the CSF.
Striatal circuit interrogation — using techniques from movement-disorder neurology (transcranial magnetic stimulation, EEG source imaging, functional connectivity analysis applied to the basal ganglia) — should be deployed directly.
The immune system becomes a secondary research target: still important, still treatable, but no longer the primary locus of investigation.
6 The fifty-thousand-person elephant in the room
The DecodeME GWAS represents real progress. It also represents a limitation. Five thousand cases is enough for the enrichment analysis to be robust — but it is not enough for the fine-mapping, gene-level association, and pathway analysis that would tell us which specific mechanisms within MSNs are disrupted.
The ME/CFS field needs a fifty-thousand-person GWAS. That number is what it has taken for schizophrenia, depression, and bipolar disorder to move from “we know it’s genetic” to “we know which biological pathways are broken” (Schizophrenia Working Group of the Psychiatric Genomics Consortium 2014). The DecodeME consortium provides the direction. Funding the next scale-up would provide the destination.
7 Certainty estimate
| Claim | Certainty |
|---|---|
| ME/CFS genetic risk variants are enriched in brain tissue (neurons) over immune cells | Very high — primary GWAS finding, statistically robust |
| Medium spiny neurons are the most enriched cell type | Moderate — from a post-GWAS cell-type analysis (preprint), dependent on the reference atlas; not from the GWAS itself |
| This rules out genetically primary immune dysfunction | High — immune enrichment is absent despite adequate power |
| This establishes the brain as the primary locus of disease | Moderate — genetics points to brain; requires converging evidence from functional studies |
| Striatal MSN enrichment is ME/CFS-specific | Unknown — other brain disorders enrich other cell types; overlap with AUD is plausible but ME/CFS/AUD convergence is unreplicated |
| The genetics changes clinical practice | Low — no diagnostic test or treatment target yet from this finding |
| Scaling to 50K+ cases would identify specific disrupted pathways | Moderate-high — based on analogous progress in psychiatric genetics |
Post 1 of 4 in the DecodeME GWAS series. Next: The Striatum Is the Bottleneck · Parkinson’s Drugs for ME/CFS? · The Striatum Isn’t Ours